Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We expect our revenue to continue to grow year-over-year, margin expansion and the net loss decrease to continue as we move towards profitability, which is always our highest priority |
| So congratulations on great growth in SilverSeal -- and if I heard you correctly, SilverSeal had very good sequential growth as well as annual |
| This is our second consecutive quarter of revenue contribution from the acquisition of a 50% interest in the JV with CG Labs |
| The return on this $500,000 investment into the JV, which we recently made the last payment on has proved to be an excellent mutually beneficial transaction and 1 in which we have quickly realized the benefits |
| We are pleased to deliver yet another record revenue quarter in Q3 of $1.22 million, an increase of 115% year-over-year and up slightly as compared to revenue of $1.17 million for the second quarter of 2023 |
| I will tell you that you're going to continue to see very strong growth from us |
| Our ability to meet the high standards of AbbVie demonstrates the uniqueness of our technology and the fact that a company of their size would select us is something we are very proud of |
| Gross margins improved sequentially to 28.1% in Q3 compared to 15% in the prior quarter |
| Importantly, we have also made significant strides improving our gross profit, going from a gross loss in Q1 to a gross profit in Q2 and improving again in Q3 |
| In North America, we are making good progress with Enigma Health for retail distribution |
| We have since launched the product and have shipped to approximately 30 ophthalmology offices and the feedback thus far has been very positive |
| Our branded consumer products grew year-over-year 54% and quarter-over-quarter by 37% |
| This was led by SilverSeal, which continues to be a hero product for us, consistently gaining popularity and positive reviews |
| Net loss also improved sequentially to $552,000 during the third quarter of 2023 as compared to $695,000 during the second quarter of 2023 |
| Now that we have fully vetted the audience for our leading products and have gained steady traction in the market, it is time to put these products on shelves |
| We're projecting profitability before we run out of cash with a pretty good cushion |
| So as far as so far, the feedback has been terrific |
| All of our meetings have gone extremely well |
| And I can say that if they are successful, this is extremely significant and impactful revenue for us |
| Before I turn the call over to Adam, while Q3 was a significant quarter for us -- we also have a lot to be excited about as we head into next year |
| We're talking to some of the patients that want to tell us some great stories |
| It has contributed materially to our top line growth and is accretive to the bottom line as well |
| The quarterly increase in overall revenues was primarily due to sales growth in contract manufacturing and branded products year-over-year, including revenue contribution from the joint venture formed with CG Labs |
| Gross margin increased sequentially to 28.2% during the third quarter of 2023 as compared to 15% during the second quarter of 2023 |
| Net loss for the quarter ended September 30, 2023, improved to $552,000 or $0.10 per basic and diluted share compared to net loss of $1.2 million or $0.22 per basic and diluted share for the same period in 2022 |
| SilverSeal was a behind-the-counter hospital device for many years, and our messaging of hospital-grade product now available for home use has resonated with our consumers |
| Given our growth into retail in new markets and our branded product line as well as the opportunity to onboard new customers, we have strategically invested in inventory and equipment to increase capacity and automation to meet the significant increase in demand we expect for our proprietary hydrogels in 2024 and beyond |
| Growth year-over-year was driven by an increase in contract manufacturing |
| There's going to be some other good things, but that 1 is staring us right in the face |
| They worked very, very well, and we’re now going ahead and ordering those guys to come in |
| Statement |
|---|
| So the main thing that we had for the 510(k) devices that pushed them off was our inability to at scale and at an effective manufacturing cost to produce them with the dies and pumps that we currently have |
| Our net loss in the third quarter also continued to trend lower quarter-over-quarter, in line with our goal to become profitable in 2024 from $814,000 in Q1 to $695,000 in Q2 to $552,000 in Q3 |
| So they're really not profitable as you start acquiring various customers |
| And was there any part of your business that struck sequentially because sequentially, your revenue did not grow that much |
| Of note, the $2.3 million in revenue generated in the last 2 quarters exceeds our full year of 2022 revenue |
| And I think what we need to determine is if everybody just going to like it because it feels so much better or are really the patients that are going to use it the ones with the worst eye irritations and the worst problems |
| And then you have to get to a certain threshold, which is probably around 25% to 30% tacos and our heroes are much lower than that, but then the products seem to be scaling |
| Total operating expenses including R&D and SG&A expenses, decreased to $956,000 for the 3 months ended September 30, 2023, compared to $1.19 million for the prior year period |
| So as of right now, our cash loss was well below $500,000, and we still have $3.3 million |
| Actual results may differ materially due to a variety of risks, uncertainties and other factors |
Please consider a small donation if you think this website provides you with relevant information